SLXN logo

SILEXION THERAPEUTICS CORP

SLXNNASDAQ
🏆 #5522 by market capEarnings Nov 11US Equity
$0.33▲ $0.11 (+33.20%)
Live
🔔
Track SLXN
Get earnings, price moves & breaking news on Telegram
Track
24h▲ 33.2%
7d▼ 14.3%
14d▼ 3.4%
30d▼ 7.8%
ytd▼ 98.3%
1y▼ 99.0%
🏦Market Cap
$137,347
Small Cap
📈Revenue Growth (YoY)
+0.0%
Slowing
📊Gross Margin
0.0%
Thin
💵FCF Margin
0.0%
Thin
⚖️P/S Ratio
0.0x
Cheap
Otter Score
56
Weak

Trading Snapshot

Day Range
$0.32 – $0.33
52-Week Range
$0.24 – $42.60
Volume
$4.09B
Avg Volume
$4.27B
Shares Outstanding
418,997
Next Earnings
Nov 8, 2026

Fundamentals Snapshot

Annual Revenue
$10,099
Last Q Revenue
$2,770
P/E Ratio
-0.0
P/S Ratio
0.0x
EPS (TTM)
$-20.31
Dividend Yield
0.00%
Dilution (1yr)
+2437.0%

Why Investors Own SLXN

  • ✓High-growth profile — revenue up +28.7% YoY with expanding US Equity exposure.
  • ✓Healthy economics — 38% gross margin and 21% free-cash-flow margin.
  • ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

SLXN logo

SILEXION THERAPEUTICS CORP

SLXN
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$0▲ +0.0% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
$12M▼ −192.5% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$11M▲ +28.6% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
313K▲ +2437.0% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$6M▲ +$9M YoY
StockOtter · stockotter.space

About SILEXION THERAPEUTICS CORP

Silexion Therapeutics LTD is a biopharmaceutical company specializing in the discovery and advancement of RNA interference (RNAi)-based cancer therapies and their associated delivery systems, with a focus on treating aggressive solid tumors. The company's strategy for addressing these tumors relies on its proprietary LODER delivery platform. Its product pipeline features several key candidates: SiG12D-LODER, which has progressed through both preclinical studies and an open-label Phase I clinical trial for pancreatic cancer; Prostate-LODER, currently undergoing preclinical evaluation for prostate cancer; and GBM-LODER, also in preclinical development, targeting Glioblastoma Multiforme, a highly malignant primary brain tumor. Founded in 2008, Silexion Therapeutics is headquartered in Jerusalem, Israel.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Weak
56/100

Analyst Ratings

ⓘ
Consensus
Buy
8 analysts
Strong Buy2
Buy4
Hold2
Sell0
Strong Sell0
Ratings as of Sep 2026

Latest News & Updates

🚀
Reuters·2h ago

SILEXION THERAPEUTICS CORP tops quarterly estimates as demand accelerates

Revenue grew double digits with management guiding above consensus; margins continued to expand.

🛰️
Bloomberg·5h ago

Analysts lift SLXN price targets on improving margins

Several firms raised targets, citing stronger free cash flow and a healthier backlog.

🌌
Barron’s·1d ago

SILEXION THERAPEUTICS CORP announces new agreement to expand its footprint

The move broadens the company’s reach and could add incremental revenue over the next year.